St. Luke's Hospital
Main Number: 314-434-1500 Emergency Dept: 314-205-6990 Patient Billing: 888-924-9200
Find a Physician Payment Options Locations & Directions
Follow us on: facebook twitter Mobile Email Page Email Page Print Page Print Page Increase Font Size Decrease Font Size Font Size
Pulmonary Rehabilitation
Pulmonary Function Testing
Respiratory Therapy
Pulmonary Physicians
The Lung Research Center
St. Luke's Pulmonary Doctors in the News
America's 50 Best Hospitals
Spirit of Women
Community Health Needs Assessment

Pulmonary Services

Pulmonary Fibrosis Study

What is Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a disease of inflammation that results in scarring, or fibrosis, of the lungs. In time, this fibrosis can build up to the point where the lungs are unable to provide oxygen to the tissues of the body. Doctors use the word "idiopathic" (from the Greek "idio" meaning "peculiar" or "unusual" and "pathy" meaning "illness") to describe the disease, because the cause of IPF is unknown. Currently, researchers believe that IPF may result from either an autoimmune disorder, a condition in which the body's immune system attacks its own tissues, or the after effects of an infection, most likely a virus. Whatever the trigger is for IPF, it appears to set off a series of events in which the inflammation and immune activity in the lungs and, eventually, the fibrosis processes, does not shut off like it's supposed to. In a few cases, heredity appears to play a part, possibly making some individuals more likely than others to get IPF. In studies of patients with IPF, the average survival rate has been found to be 4 to 6 years after diagnosis. Those who develop IPF at a young age seem to have a longer survival.

September is Pulmonary Fibrosis Awareness month. In honor of this, the Discovery Channel is airing a documentary about Pulmonary Fibrosis on September 13 and September 27 at 7 p.m.

Idiopathic Pulmonary Fibrosis Clinical Trials
Currently Enrolling:


MedImmune (CD-RI-CAT-354-1066): A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults with Idiopathic Pulmonary Fibrosis.

Purpose: To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). Participation could last up to 90 weeks.

Fibrogen (FGLC-3019-067): A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis.

Purpose: To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects. Participation could last approximately 2 years.

RIFF (GB28547): A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis.

Purpose: This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in patients with idiopathic pulmonary fibrosis. Patients will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.

Lebrickizumab is an injectable medication given every 4 weeks intended to slow the progression of IPF. Participation could last from 1 to 2.5 years.

RAINIER (GS-US-322-0207):A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF).

Purpose: The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis.

Simtuzamab is a weekly injectable medication intended to slow the progression of IPF. Participation could last up to 3.5 years.

Patient Brochure - PDF PDF

IM136003: Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis.

Purpose: The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF). Participation could last up to 34 weeks.

PIPF-031(Extended Access Program)
A treatment protocol to allow patients in the US with IPF access to Pirfenidone.

Clinical Trials (Closed to Enrollment):

BIPI 1199.33 Extension: An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF).

Purpose: The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.

Status: Active, Not Recruiting Patients

FIBROGEN (FG-3019-049): A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis

Purpose: To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.

Status: Active, Not Recruiting Patients

Pulmonary Function Testing (PFT)

For All Studies:
Qualified participants will receive study-related care, study-related exams and study-related medication at no cost. Participants may be compensated for their time and travel.

If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: thelungcenter@stlukes-stl.com.

Dr. Ettinger: Idiopathic Pulmonary Fibrosis (IPF)

Back  |  Top
About Us
Contact Us
History
Mission
Locations & Directions
Quality Reports
Annual Reports
Honors & Awards
Community Health Needs
Assessment

Newsroom
Services
Brain & Spine
Cancer
Heart
Maternity
Orthopedics
Pulmonary
Sleep Medicine
Urgent Care
Women's Services
All Services
Patients & Visitors
Locations & Directions
Find a Physician
Tour St. Luke's
Patient & Visitor Information
Contact Us
Payment Options
Financial Assistance
Send a Card
Mammogram Appointments
Health Tools
My Personal Health
mystlukes
Spirit of Women
Health Information & Tools
Clinical Trials
Health Risk Assessments
Employer Programs -
Passport to Wellness

Classes & Events
Classes & Events
Spirit of Women
Donate & Volunteer
Giving Opportunities
Volunteer
Physicians & Employees
For Physicians
Remote Access
Medical Residency Information
Pharmacy Residency Information
Physician CPOE Training
Careers
Careers
St. Luke's Hospital - 232 South Woods Mill Road - Chesterfield, MO 63017 Main Number: 314-434-1500 Emergency Dept: 314-205-6990 Patient Billing: 888-924-9200
Copyright © St. Luke's Hospital Website Terms and Conditions  |  Privacy Policy  |  Patient Notice of Privacy Policies PDF Sitemap St. Luke's Mobile